Association of PLA2G7 polymorphisms with carotid atherosclerosis in hypertensive Japanese

Hypertension Research

Volumn 32, Issue 12, 2009, Pages 1112-1118

  Miwa, Yoshikazu ^a,b   Kamide, Kei ^a   Takiuchi, Shin ^a   Yoshii, Masayoshi ^a   Horio, Takeshi ^a   Tanaka, Chihiro ^a   Banno, Mariko ^a   Miyata, Toshiyuki ^a   Kawano, Yuhei ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Intima media thickness; PAF AH; PLA2G7; Polymorphism

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALANINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ISOLEUCINE; PHENYLALANINE; THREONINE; VALINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY; CAUCASIAN; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; RISK FACTOR; WILD TYPE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CAROTID ARTERY DISEASES; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; JAPAN; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PHOSPHOLIPASES A2; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION;

EID: 73849143385     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.151     Document Type: Article

References (34)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.
3. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 2002; 22: 727-733.
4. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93-114.
5. Blank ML, Lee T, Fitzgerald V, Snyder F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 1981; 256: 175-178.
6. Min JH, Wilder C, Aoki J, Arai H, Inoue K, Paul L, Gelb MH. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry 2001; 40: 4539-4549.
7. Tsukioka K, Matsuzaki M, Nakamata M, Kayahara H, Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig Allergol Clin Immunol 1996; 6: 22-29.
8. Triggiani M, De Marino V, Sofia M, Faraone S, Ambrosio G, Carratu L, Marone G. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med 1997; 156: 94-100.
9. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1990; 91: 244-256.
10. Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhy-drolase activity. Arthritis Rheum 1999; 42: 373-383.
11. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82: 1983-1991.
12. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97: 2784-2791.
13. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279-4Phe) is a genetic risk factor for stroke. Stroke 1997; 28: 2417-2420.
14. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994-4 T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47: 177-181.
15. Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J, Miwa M, Nakamura S. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg 2000; 32: 263-267.
16. Bell R, Collier DA, Rice SQ, Roberts GW, MacPhee CH, Kerwin RW, Price J, Gloger IS. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem Biophys Res Commun 1997; 241: 630-635.
17. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000; 66: 1522-1530.
18. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37: 541-546.
19. Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D. Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 2001; 38: 1162-1166.
20. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Takamatsu M. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipopro-tein from patients with essential hypertension. Prostaglandins 1989; 37: 673-682.
21. Kamide K, Takiuchi S, Tanaka C, Miwa Y, Yoshii M, Horio T, Mannami T, Kokubo Y, Tomoike H, Kawano Y, Miyata T. Three novel missense mutations of WNK4, a kinase mutated in inherited hypertension, in Japanese hypertensives: implication of clinical phenotypes. Am J Hypertens 2004; 17: 446-449.
22. Kamide K, Tanaka C, Takiuchi S, Miwa Y, Yoshii M, Horio T, Kawano Y, Miyata T. Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives. Hypertens Res 2004; 27: 333-338.
23. Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y, Miyata T. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 2003; 26: 301-306.
24. Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, Tanaka C, Banno M, Miyata T, Sasaguri T, Kawano Y. Identification of gene polymorphism in lipocalin-type prosta-glandin D synthase and its association with carotid atherosclerosis in Japanese hypertensive patients. Biochem Biophys Res Commun 2004; 322: 428-433.
25. Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, Tanaka C, Banno M, Miyata T, Sasaguri T, Kawano Y. Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun 2005; 331: 1587-1593.
26. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93-114.
27. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem 2004; 50: 2077-2082. (Pubitemid 39425845)
28. Morgan EN, Boyle Jr EM, Yun W, Kovacich JC, Canty Jr TG, Chi E, Pohlman TH, Verrier ED. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999; 100(Suppl II): 365-368.
29. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500.
30. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150: 209-216.
31. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
32. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202-2212.
33. Aengevaeren WR. Beyond lipids-the role of the endothelium in coronary artery disease. Atherosclerosis 1999; 147(Suppl 1): S11-S16.
34. Yoshimura T, Ohshige A, Maeda T, Ito M, Okamura H. Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women. Maturitas 1999; 31: 249-253.